Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | PDXK | O00764 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.56 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.54 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxine SCHEMBL2322958 | 0.98 | HPGD (1.00) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL30877002 | 0.98 | HPGD (1.00) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL30267871 | 0.98 | HPGD (1.00) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL3506 | 0.98 | HPGD (1.00) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL5370659 | 0.96 | HPGD (0.96) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL3497798 | 0.96 | HPGD (0.96) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL444525 | 0.96 | KDM4E (0.96) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL8733421 | 0.96 | HPGD (0.96) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL7588196 | 0.96 | KDM4E (0.96) | HPGDKDM4EALDH1A1HSD17B10LMNA | |
| Pyridoxine SCHEMBL5611277 | 0.96 | HPGD (0.96) | HPGDKDM4EALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370449-A1 | COMBINED PHARMACEUTICAL COMPOSITION | GIDD COMMERCIAL USA, INC. | 2022-11-24 | — | — | US | claimed |
| US-11406636-B2 | Combined pharmaceutical composition | GIDD COMMERCIAL USA, INC. (US) | 2022-08-09 | — | — | US | claimed |
| US-20190183892-A1 | COMBINED PHARMACEUTICAL COMPOSITION | GIDD COMMERCIAL USA, INC. | 2019-06-20 | — | — | US | claimed |
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | CAVALIER DISCOVERY | 2003-05-01 | — | — | US | claimed |
| WO-2002100478-A9 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2003-03-27 | — | — | WO | claimed |
| WO-2002100478-A2 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2002-12-19 | — | — | WO | claimed |
| US-20190000802-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | VICUS THERAPEUTICS LLC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180169069-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170333396-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20160158198-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-2374508-A1 | Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2374458-A1 | Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20090215852-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | CHROMA GROUP, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-2054052-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | Vicus Therapeutics SPE 1, LLC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1990049-A2 | Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID) | Vicus Therapeutics SPE 1, LLC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080033027-A1 | Drug combination pharmaceutical compositions and methods for using them | VICUS THERAPEUTICS SPE 1, LLC (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2008014471-A1 | DRUG COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM | VICUS THERAPEUTICS SPE 1, LLC (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | CAVALIER DISCOVERY | 2003-05-01 | — | — | US | disclosed |
| WO-2002100478-A9 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002100478-A2 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | SOD1, SOD3, APEX1 | HPGD 473/4885KDM4E 4536/4885ALDH1A1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.